Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Posttraumatic Stress Disorder (PTSD) Treatment: Using Ketamine to Enhance Memory Reconsolidation and Extinction of Overgeneralized Fear in Individuals Diagnosed With PTSD

NCT05737693 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT05737693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05737693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Posttraumatic Stress Disorder (PTSD) Treatment: Using Ketamine to Enhance Memory Reconsolidation and Extinction of Overgeneralized Fear in Individuals Diagnosed With PTSD
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 21, 2023
Completion date
August 1, 2031
Enrollment
350 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

posttraumatic stress disorder